Adherence and long-acting injectable antipsychotics in schizophrenia: an update

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F12%3A43913824" target="_blank" >RIV/00023752:_____/12:43913824 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.5350/DAJPN20122504001" target="_blank" >http://dx.doi.org/10.5350/DAJPN20122504001</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5350/DAJPN20122504001" target="_blank" >10.5350/DAJPN20122504001</a>

Result language
angličtina
Original language name
Adherence and long-acting injectable antipsychotics in schizophrenia: an update
Original language description
Nonadherence to antipsychotics poses a major problem in the long-term management of schizophrenia. Subjective measures of adherence (self-reports, provider reports) are unreliable, more objective methods (e.g., electronic monitoring, plasma levels) are neither available in clinical practice, nor are they infallible. Risk factors include history of nonadherence, substance use, limited insight, treatment with antidepressants, medication-induced cognitive impairment, hostility, and violent behavior. Nonadherence results in partial or no response to antipsychotic treatment with many adverse consequences, including higher mortality. A recent meta-analysis somewhat surprisingly failed to prove higher adherence to long-acting injectable antipsychotics (LAI) than to oral antipsychotics. However, unexpectedly high adherence in the reviewed trials suggests selection bias. This is further supported indirectly by the findings from two large observational studies from Finland. They showed that LAI,
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FL - Psychiatry, sexology
OECD FORD branch
—

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)